Monitoring of stem cell sector market capitalization

by Alexey Bersenev on January 23, 2009 · 3 comments

in business

Post to Twitter

I’d like to introduce a new blog, monitoring stem cell companies financial and market capitalization monthly – Stem Cell Digest.

their calculation based on analysis of reports of public companies:

Criteria for inclusion are: Between 5 million and 500 million in market value; publicly traded on a North American stock exchange; and the company has, as its primary source of revenue, stem cell related activities. StemCellDigest.Net takes no position on the quality of products, the research, or the financial viability of any company in the sector. They are described here because they meet the criteria set forth and not for any other reason. If your company fits these criteria and is not included, please let us know and it will be added.


(published with permission; creadit: Gary Eastin / Stem Cell Digest)

subscribe by RSS and keep yourself updated!

*****************

read and watch more about business this week:

video-interview with Randy Mills – CEO of Osiris Therapeutics – “The Tremendous Therapeutical and Commercial Applications of Mesenchymal Stem Cells” (by BioBusiness.TV)
Q&A with Randall Mills, Osiris Therapeutics (by Pharmaceutical Executive)
Interview with a president of CIRM Alan Trounson – “The Future of Regenerative Medicine” (by (Pharma TV)

{ 3 comments… read them below or add one }

Art January 24, 2009 at 8:30 am

Very interesting… all Nasdaq go down, stem-cell – up. Obama’s phenomen :) congratulation!

Reply

Alex January 25, 2009 at 3:06 pm
Alex January 25, 2009 at 3:52 pm

Reaction of investors was general: whole stem cell field got their attention,
for example: STEM (Nasdaq) –
STEM

Reply

Leave a Comment

Previous post:

Next post: